Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Slides:

Advertisements

Similar presentations

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Statement—Recommendations for Prevention and Control of Influenza in Children,

Advertisements

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 1 Overview of Markov model for infected total hip arthroplasty

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 1. Baseline Characteristics of the 36,636 Study Subjects

Figure 1. Disposition of study participants, by group. Data are no

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

From: Rotarix: A Rotavirus Vaccine for the World

Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, From: Evaluation.

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Table 1 Criteria for proven invasive fungal disease except for endemic mycoses. From: Revised Definitions of Invasive Fungal Disease from the European.

Table 1 Characteristics of study population, by pneumococcal vaccination status. From: Prior Pneumococcal Vaccination Is Associated with Reduced Death,

From: Postinfectious Irritable Bowel Syndrome

Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,

Figure 2 In situ hybridization for rhinovirus type 14 (rhinovirus-14) in maxillary sinus biopsy specimens. A, Detection of rhinovirus-14, antisense probe,

Table 5 Sample format for results of Streptococcus pneumoniae isolate testing in a laboratory that routinely performs only oxacillin disk tests for penicillin.

Table 1 Baseline (before receipt of antiretroviral prophylaxis) characteristics of the pregnant women (transmitting or nontransmitting mothers included.

Figure 1 Annual per-capita consumption of all fermented milks and yogurt only in selected countries in Europe and North America [3, 4]. From: Probiotic.

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

R. Cavallo Clinical Microbiology and Infection

Twelve years of dengue surveillance in Belgian travellers and significant increases in the number of cases in 2010 and 2013 J. Verschueren, L. Cnops,

Rapid antigen testing for the surveillance of influenza epidemics

C. Steininger, M. Redlberger, W. Graninger, M. Kundi, T. Popow-Kraupp

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

Serotypes, biotypes and antimicrobial susceptibilities of Haemophilus influenzae isolated from invasive disease in children in Casablanca N. Moustaoui,

Cutaneous sporotrichosis: the old iodide treatment remains effective

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children M. Jones, T. Jefferson,

Sofie Arens, Jan Verhaegen, Ludo Verbist

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

G. Höffken Clinical Microbiology and Infection

Human metapneumovirus infection among children in Taiwan: a comparison of clinical manifestations with other virus-associated respiratory tract infections

Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis J. Poissy, M. Wolff, A. Dewilde, F.

Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis J.-W. Yang, L.-C. Fan, X.-Y. Miao, B.

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

Levofloxacin in the treatment of ventilator-associated pneumonia

Seasonal H1N influenza virus infection is associated with elevated pre‐exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus M.

J. Garau Clinical Microbiology and Infection

Reducing antibiotic use in influenza: challenges and rewards

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy L. Boglione,

Use of a multiplex real-time PCR to study the incidence of human metapneumovirus and human respiratory syncytial virus infections during two winter seasons.

An after-hours clinical liaison blood culture service—is it worth it?

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Genomic diversity of group A rotavirus strains in patients aged 1–36 months admitted for acute watery diarrhoea in northern India: a hospital-based study

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Q Fever: Epidemiology, Diagnosis, and Treatment

L. Bichaud, R. P. Piarroux, A. Izri, L. Ninove, C. Mary, X

Number of 2019–2020 seasonal influenza vaccine doses for children based on age and previous vaccination history and recommendations for prevention and.

Presentation transcript:

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4):439-444. doi:10.1086/505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Table 1 Characteristics of patients in a comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4):439-444. doi:10.1086/505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Table 5 Duration of fever for influenza A and influenza B, by patient age. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4):439-444. doi:10.1086/505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Table 4 Duration of fever after administration of the first dose of oseltamivir for influenza A or influenza B, by patient age. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4):439-444. doi:10.1086/505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Table 3 Duration of fever for patients with influenza A and those with influenza B, by time to the first administration of oseltamivir after the onset of fever. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4):439-444. doi:10.1086/505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Table 2 Duration of fever after administration of the first dose of oseltamivir for patients with influenza A or influenza B, by time to administration of the first dose after the onset of fever. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003–2004 and 2004–2005 Influenza Seasons Clin Infect Dis. 2006;43(4):439-444. doi:10.1086/505868 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America